Category Archives: Safety

Pharma Still Doesn't Get Patient Groups

A survey of 600 patient groups worldwide conducted in late 2012 revealed that perceptions of the pharmaceutical industry soured in the past year, mainly due to issues of access, pricing, patient safety and transparency. The Corporate Reputation of Pharma in 2012—the Patient Perspective compared the reputations of 29 leading pharma companies around six different [...]
Also posted in Europe, Market Access, Strategy, patient education, pricing | Tagged , , | Leave a comment

The Year to Come: EMA's Plans Announced

At the end of last month, the European Medicines Agency approved its budget and work program for the coming year, promising to implement measures to increase operational efficiency, enhance transparency and communication with stakeholders, and improve the quality and consistency of rulemaking. With a 4.1% increase in budget to €231.6 million and an anticipated 54 [...]
Also posted in Europe, Regulatory, Strategy | Tagged , , , | Leave a comment

New Pseudoephedrine Drug Could Hop Back Over the Counter

Yesterday Acura Pharmaceuticals launched its new pseudoephedrine-based product Nexafed, an over-the-counter product aimed at deterring abuse of the illicit drug methamphetamine. Pseudoephedrine, the decongestant known also as the primary ingredient in the production of methamphetamine, has been subject to a federal statute which keeps medicines with the ingredient behind the counter of all pharmacies in [...]
Also posted in Market Access, Strategy | Tagged | 1 Comment

US v. Caronia: What Constitutes 'Truthful' Speech?

If a drug’s label is not the final word on what is true – or untrue – about a product, then who decides what can and cannot be said during a sales detail?
Also posted in Advertising, FDA, Legal, Marketing, Regulatory, Sales, Strategy, compliance | Tagged , , , , , , , , , , , , , , , , , , | 1 Comment

Pharma's Reputation: A Boost in the US, but China Strikes a Sour Note

The pharmaceutical industry’s global reputation is on the mend, even if some countries – notably China – are more hostile, according to the latest Ipsos Reputation Snapshot for the Pharmaceutical Sector, from the Ipsos Global Reputation Centre. Since the last Ipsos survey in 2008, pharma’s reputation has improved significantly in the US, more so than in [...]
Also posted in Corporate Responsibility, Emerging Markets, Strategy | Tagged | Leave a comment